Please login to the form below

Not currently logged in
Email:
Password:

biosimilars

This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

The breakthrough is thanks to a Roche discount on Perjeta – but most especially because of the arrival of cheaper Herceptin (trastuzumab) biosimilars, which have brought down the cost of combination treatment ... Herceptin sales reached $6.94bn last

Latest news

  • Industry aghast as EU Parliament backs biosimilar rule change Industry aghast as EU Parliament backs biosimilar rule change

    At the moment generic and biosimilar manufacturers cannot manufacture their copycat products during the SPC period. ... European generic and biosimilar companies have long argued however that the waiver hands an unfair advantage to competitors outside

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    The latter are already under pressure on pricing and increased competition and are in the sights of US lawmakers and the FDA who want to see faster biosimilar competition to these

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    Good news after Alzheimer's failure. Roche saw a decline in its European sales last year as biosimilars started to bite its blockbuster biologic drugs, but strong growth for new products ... The result was stronger than expected, given that earlier this

  • IQVIA sees market slowdown looming for pharma IQVIA sees market slowdown looming for pharma

    The overarching market figures don’t reveal the big changes for different product categories beneath, however, and IQVIA is predicting “explosive” growth in biosimilars, which will result in approximately $160bn in ... All told, 18 of the current

  • Hardy returns to Genentech as CEO Hardy returns to Genentech as CEO

    Both Hardy and Anderson have their work cut out for them though, as the companies are currently trying to navigate through an onslaught of biosimilars, which are threatening to offset sales ... It’s a slightly different story for the EU however, where

More from news
Approximately 131 fully matching, plus 272 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 53 partially matching documents found.

Latest appointments

  • Ashfield, Health Unlimited and Ashley Communications add to their teams Ashfield, Health Unlimited and Ashley Communications add to their teams

    Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop

  • PharmaLex appoints Zabin Younes as associate director PharmaLex appoints Zabin Younes as associate director

    She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    Novartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • NHS medicines optimisation milestone

    Tackling variations in the uptake of biosimilars locally has been a key focus for RMOCs. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS Improvement and NHS Clinical

  • New local NHS models help to deliver integrated care

    A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections

  • OPEN Access Consulting

    What OPEN Access Consulting do:. We have unrivalled experience in the delivery of market access programmes from early phase insights to generic/biosimilar strategies. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. . ... Biosimilar Cost-Savings in Reality

  • Ashfield launches new commercial model to improve ROI

    The transformational new model helps pharmaceutical companies optimise their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars.

More from PMHub
Approximately 13 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....

Infographics